CD44 and cancer: Bourseau-Guilmain et al. (2011) prepared lipoprotein-like nanocapsules to deliver AC133 to effectively target CD133 positive CSCs. A CD44-specific tumor-targeting drug was carried by HA for the cancer therapy (Marhaba et al., 2008). An anti-CD90 antibody was also proved to be able to stop the bone marrow-derived multipotent stromal cells to differentiate into chondro-, osteogenic, or adipo-lineages (Gundlach et al., 2011).